Abstract
IntroductionTwo novel agents, dabigatran and rivaroxaban, recently gained market authorisation for prevention of venous thromboembolism (VTE) after hip and knee arthroplasty. However, safety data of the new oral anticoagulants with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have